<?xml version='1.0' encoding='utf-8'?>
<document id="32026490"><sentence text="A Drug-Drug Interaction Study to Evaluate the Effect of TAS-303 on CYP3A Activity in the Small Intestine and Liver." /><sentence text="TAS-303 (4-piperidinyl 2,2-diphenyl-2-[propoxy-1,1,2,2,3,3,3-d7 ] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence"><entity charOffset="0-87" id="DDI-PubMed.32026490.s2.e0" text="TAS-303 (4-piperidinyl 2,2-diphenyl-2-[propoxy-1,1,2,2,3,3,3-d7 ] acetate hydrochloride" /><entity charOffset="110-123" id="DDI-PubMed.32026490.s2.e1" text="noradrenaline" /><pair ddi="false" e1="DDI-PubMed.32026490.s2.e0" e2="DDI-PubMed.32026490.s2.e0" /><pair ddi="false" e1="DDI-PubMed.32026490.s2.e0" e2="DDI-PubMed.32026490.s2.e1" /></sentence><sentence text=" An in vitro study and a physiologically based pharmacokinetic model simulation showed that TAS-303 had inhibitory potential against cytochrome P450 (CYP) 3A" /><sentence text=" This open-label, single-group study investigated the effect of TAS-303 on CYP3A activity by evaluating the pharmacokinetics (PK) of single-dose oral simvastatin 5 mg or intravenous midazolam 1 mg after repeated oral administration of TAS-303 3 mg in 12 healthy participants"><entity charOffset="150-161" id="DDI-PubMed.32026490.s4.e0" text="simvastatin" /><entity charOffset="182-191" id="DDI-PubMed.32026490.s4.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.32026490.s4.e0" e2="DDI-PubMed.32026490.s4.e0" /><pair ddi="false" e1="DDI-PubMed.32026490.s4.e0" e2="DDI-PubMed.32026490.s4.e1" /></sentence><sentence text=" TAS-303 plus simvastatin resulted in a 1"><entity charOffset="14-25" id="DDI-PubMed.32026490.s5.e0" text="simvastatin" /></sentence><sentence text="326-fold and a 1" /><sentence text="420-fold increase of simvastatin in peak plasma concentration and area under the plasma concentration-time curve from time zero to time t, where t is the final time of detection (AUC0-t ), respectively"><entity charOffset="21-32" id="DDI-PubMed.32026490.s7.e0" text="simvastatin" /></sentence><sentence text=" The addition of midazolam resulted in a 1"><entity charOffset="17-26" id="DDI-PubMed.32026490.s8.e0" text="midazolam" /></sentence><sentence text="090-fold increase in the midazolam AUC0-t " /><sentence text=" TAS-303 had a weak PK interaction with simvastatin but no apparent interaction with midazolam"><entity charOffset="40-51" id="DDI-PubMed.32026490.s10.e0" text="simvastatin" /><entity charOffset="85-94" id="DDI-PubMed.32026490.s10.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.32026490.s10.e0" e2="DDI-PubMed.32026490.s10.e0" /><pair ddi="false" e1="DDI-PubMed.32026490.s10.e0" e2="DDI-PubMed.32026490.s10.e1" /></sentence><sentence text=" TAS-303 at 3 mg/day is a weak inhibitor of intestinal but not hepatic CYP3A activity" /><sentence text=" No clinically important safety concerns related to TAS-303 were raised" /><sentence text="" /></document>